Swiss National Bank acquired a new stake in NeoGenomics Inc. (NASDAQ:NEO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 95,400 shares of the company’s stock, valued at approximately $767,000. Swiss National Bank owned 0.12% of NeoGenomics as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Suntrust Banks Inc. bought a new position in NeoGenomics during the second quarter valued at about $114,000. Fox Run Management L.L.C. acquired a new stake in NeoGenomics during the second quarter worth $171,000. Bank of Montreal Can acquired a new stake in NeoGenomics during the second quarter worth $640,000. ClariVest Asset Management LLC acquired a new stake in NeoGenomics during the second quarter worth $644,000. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in NeoGenomics by 14,127.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 142,276 shares of the company’s stock worth $959,000 after buying an additional 141,276 shares during the last quarter. Institutional investors own 77.20% of the company’s stock.
Shares of NeoGenomics Inc. (NASDAQ:NEO) traded down 0.74% during trading on Friday, hitting $8.02. 176,197 shares of the stock were exchanged. The firm has a 50 day moving average price of $8.11 and a 200 day moving average price of $8.11. The firm’s market capitalization is $624.70 million. NeoGenomics Inc. has a 52 week low of $5.49 and a 52 week high of $9.54.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 26th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The company earned $63.10 million during the quarter, compared to analysts’ expectations of $61.07 million. NeoGenomics had a negative net margin of 3.76% and a positive return on equity of 3.18%. NeoGenomics’s quarterly revenue was up 159.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.01 EPS. Analysts forecast that NeoGenomics Inc. will post $0.13 EPS for the current fiscal year.
A number of equities analysts have commented on NEO shares. Benchmark Co. boosted their price target on shares of NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, July 27th. Zacks Investment Research upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research report on Friday, August 5th. Craig Hallum restated a “buy” rating on shares of NeoGenomics in a research report on Saturday, July 9th. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of NeoGenomics in a research report on Friday, July 8th. Finally, Raymond James Financial Inc. started coverage on shares of NeoGenomics in a research report on Thursday, September 8th. They issued an “outperform” rating and a $10.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. NeoGenomics presently has an average rating of “Buy” and a consensus price target of $10.41.
In other news, insider Maher Albitar sold 105,300 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $8.20, for a total transaction of $863,460.00. Following the completion of the sale, the insider now owns 105,300 shares in the company, valued at approximately $863,460. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 12.20% of the company’s stock.
NeoGenomics Company Profile